



PRESS RELEASE

21 January 2026 08:30:00 CET

BOULE DIAGNOSTICS RENEWS AND EXPANDS A GLOBAL SUPPLY AGREEMENT

Clinical Diagnostics Solutions (CDS), a Boule Diagnostics company in the US, announces that its supply agreement with a leading global In Vitro Diagnostics (IVD) customer has been renewed and expanded. The extended agreement is a result of the trust in CDS and the work to innovate for diagnostic technologies worldwide.

The agreement is expected to increase sales by approximately SEK 5 million once the project is fully implemented in 2027 and have a good operating margin. This expansion strengthens Boule's strategic focus on long-term partnerships and profitable growth. *"This agreement underlines the confidence in CDS's solutions and strengthens our role in advancing health diagnostics globally,"* says Torben Nielsen, CEO of Boule Diagnostics. *"We look forward to continuing to deliver value and be a trusted supplier to our partners."*

Contacts

Torben Nielsen, CEO and Group President, torben.nielsen@boule.com, phone +46 (0) 70-558 51 05

Holger Lembrér, CFO, holger.lembrer@boule.com, phone +46 (0)72-230 77 10

About Us

Boule Diagnostics AB (publ) is a global company consisting of two business segments, Diagnostics and OEM CDS. Diagnostics is specialized in near-patient, decentralized diagnostic solutions for human and veterinary applications, serving hospitals, clinics, laboratories. OEM CDS develops and delivers reliable reagent, blood controls and calibrators tailored for diagnostic companies worldwide.

With operations in Sweden, the United States, Mexico, and Russia, and a global distribution network spanning more than 100 countries, Boule combines a resilient business model with strong positions in key growth markets. In 2024, Boule reported net sales of SEK 558 million and has about 200 employees worldwide. Boule has been listed on Nasdaq Stockholm since 2011. <http://www.boule.com>